Targeting NLRP3 with GDC-2394 ameliorates airway inflammation and smooth muscle hyperplasia in experimental asthma by suppressing the IL-6/JAK2/STAT3 axis Authors: Zhiyuan Wang, Zhenzhen Guo, Yanan Wang, Qianqian Dai, Muhammad Imran Arif, Aizetiguli Maiming, Menghua Li, Aliya Maimaitiniyazi, Xueli Wang, Jianjiang Cui, Shengmeng Qu, Wen Zhao, Liang Ru Published: 2026 ABSTRACT AbstractUncontrolled childhood asthma contributes to chronic airway inflammation and remodeling, primarily characterized by bronchial smooth muscle hyperplasia. Although the NLR family pyrin domain-containing 3 (NLRP3) inflammasome regulates airway inflammation, its role in abnormal airway smooth muscle cell (ASMC) proliferation remains poorly understood. Here, we evaluated the selective NLRP3 inhibitor GDC-2394 in a house dust mite (HDM)-induced murine model of asthma with a vehicle control group, focusing on the NLRP3–IL-6/JAK2/STAT3 signaling axis. HDM-challenged mice displayed increased airway hyperresponsiveness, elevated levels of eosinophils, IgE, IL-1β, IL-18, type 2 cytokines, and IL-6, as well as marked airway inflammation, smooth muscle thickening, goblet cell hyperplasia, and mucus hypersecretion. Vehicle alone showed no significant effects. GDC-2394 treatment attenuated these pathological changes, supporting the specificity of the drug. Mechanistically, pharmacological NLRP3 inhibition reduced ASMC hyperplasia in association with decreased IL-6–induced phosphorylation of JAK2 and STAT3, without affecting their mRNA expression levels. These findings suggest that NLRP3 may contribute to ASMC hyperproliferation, at least in part through the IL-6/JAK2/STAT3 pathway, in experimental asthma. While these results support a role for ASMCs, immune cell populations may also contribute. These data warrant further investigation of NLRP3 inhibition as a potential strategy against airway remodeling in asthma.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1038/s41598-026-63715-5.Keywords: NLRP3 inflammasome, Airway smooth muscle hyperplasia, IL-6/JAK2/STAT3 pathway, GDC-2394, Airway remodeling, Chronic allergic asthmaSubject terms: Cell biology, Diseases, Immunology, Medical research, Pathogenesis Introduction Asthma is a heterogeneous disease characterized by chronic airway inflammation and airway hyperresponsiveness (AHR)1. The majority of cases exhibit elevated type 2 inflammation driven by T-helper type 2 (Th2) and group 2 innate lymphoid cells (ILC2s), with increased IL-4, IL-5, and IL-132. Uncontrolled asthma can lead to irreversible airway remodeling, including epithelial damage, goblet cell hyperplasia, subepithelial fibrosis, and airway smooth muscle hypertrophy, which are particularly prominent in severe or chronic disease3–5. Airway smooth muscle cells (ASMCs) are important contributors to asthma pathogenesis through abnormal contraction, hyperplasia, and secretion of pro-inflammatory and angiogenic mediators5,6. Current therapeutic strategies targeting ASMCs primarily rely on β-agonists for symptomatic relief, without addressing the underlying disease mechanisms. Moreover, prolonged use of β-agonists may result in receptor desensitization, accelerated airway remodeling, and increased mortality risk7,8. Therefore, novel therapeutic approaches aimed at modulating ASMC behavior are currently being investigated9,10. Several recent studies have explored novel asthma treatments using ASMC-focused approaches10. The NLR family pyrin domain-containing 3 (NLRP3) inflammasome complex, a small molecule that is intricately associated with inflammatory responses, has been linked to various respiratory ailments, including COPD9,11 and pneumonia12. Of particular interest, the NLRP3 inflammasome has been consistently shown to be aberrantly activated during asthma pathogenesis13–15. Genetic deletion of NLRP3 (Nlrp3−/−) significantly reduced eosinophilia, IL-6 levels, and type-2 cytokine production in allergic asthma16. Furthermore, the pharmacological inhibition of NLRP3 effectively alleviated pathological changes induced by exposure to house dust mites (HDMs)17. Notably, the IL-6/JAK2/STAT3 signaling pathway has been identified as a mediator of ASMC proliferation and airway remodeling18,19. Based on the current evidence, we hypothesize that NLRP3 contributes to ASMC dysfunction and type-2 inflammatory responses via activation of the IL-6/JAK2/STAT3 pathway—a mechanism not yet been fully elucidated in asthma. In this study, we targeted NLRP3, an upstream node of this pathway, for therapeutic intervention using the selective small-molecule NLRP3 inhibitor GDC-2394. As an orally bioavailable NLRP3 antagonist, GDC-2394 selectively inhibits the secretion of IL-1β and IL-18 induced by NLRP3 inflammasome activation20. We administered GDC-2394 to an asthmatic murine model to evaluate the in vivo efficacy of NLRP3 inhibition in suppressing downstream pathway activation. This study aimed to elucidate the role of NLRP3 in the pathogenesis of experimental asthma, with a particular focus on ASMCs. Although NLRP3 is expressed in multiple peribronchial and inflammatory cell types, we focused on ASMCs because their abnormal proliferation contributes to airway remodeling and is not adequately addressed by current bronchodilator-based therapies. We therefore combined an in vivo pharmacological model with primary ASMC culture to investigate whether NLRP3 inhibition attenuates ASMC proliferation and to explore the underlying IL-6/JAK2/STAT3 signaling in chronic asthmatic airway remodeling. Materials and methods Materials House dust mite (HDM) was obtained from Greer (CAT#: XPB82D3A2.5, D.pteronyssinus, Greer, USA). GDC-2394 was purchased from MedChemExpress (CAT#: HY-148258, MedChemExpress, New Jersey, USA). Experimental animals Forty female C57BL/6 mice (aged 3–4 weeks; body weight 10–12 g) with specific pathogen-free status were obtained from the Animal Experiment Center of Xinjiang Medical University (License numbers: Production SCXK (Xin) 2018–0002; Use SYXK (Xin) 2018–0003) and housed at the same facility under controlled environmental conditions: Temperature: 20–26 °C, Humidity: 40–70%, Light cycle: 12-h light/dark cycle. Establishment of a chronic asthma airway remodeling model in mice and experimental groups Based on a study by Woo et al.21, a chronic allergic asthma mouse model was established. Mice were randomly divided into four groups (n = 10 per group): Control (PBS), HDM, HDM + Vehicle, and HDM + GDC-2394. On days 0, 1, 2, 3, and 4, HDM was administered intranasally to sedated mice in the HDM, HDM + Vehicle, and HDM + GDC-2394 groups at a dose of 25 μg/25 μL phosphate-buffered saline (PBS) for sensitization; the Control group received an equivalent volume of PBS. During the stimulation phase, mice in the HDM, HDM + Vehicle, and HDM + GDC-2394 groups received intranasal HDM at 25 μg/25 μL PBS for 5 consecutive days per week over 3 weeks; the Control group received PBS following the same schedule. The HDM + Vehicle and HDM + GDC-2394 groups received daily oral gavage starting in the third week of HDM stimulation. GDC-2394 was dissolved in DMSO to prepare a stock solution (20.8 mg/mL). The stock solution was then diluted 1:9 (v/v) in physiological saline containing 20% (w/v) SBE-β-CD to yield a working solution of approximately 2.08 mg/mL. For each mouse (body weight ~ 15 g), 72 μL of the working solution (containing 150 μg GDC-2394) was added to 200 μL corn oil and mixed thoroughly. The resulting suspension (~ 272 μL total volume) was administered by oral gavage once daily at a dose of 10 mg/kg. The HDM + Vehicle group received an equivalent volume (72 μL) of vehicle working solution (DMSO diluted 1:9 in 20% SBE-β-CD saline, without GDC-2394) mixed with 200 μL corn oil, following the same administration schedule. The experimental design is shown in Fig. 1a. Experimental design of the HDM-induced asthma model and GDC-2394 intervention. (a) Schematic workflow of HDM sensitization, challenge, and GDC-2394/vehicle intervention in four experimental groups. (b) Body weights recorded 24 h after the final AHR assessment. Significant weight loss was observed in the HDM, HDM + Vehicle, and HDM + GDC-2394 groups compared with the Control group (****P < 0.0001). No significant difference was observed between the HDM and HDM + Vehicle groups (ns, P = 0.2066). (c) Airway hyperresponsiveness assessed by enhanced pause (Penh) values after methacholine challenge at increasing concentrations (0–50 mg/mL). The HDM + Vehicle group showed a similar pattern of AHR to the HDM group, confirming no vehicle effect on airway responsiveness. (d, e) Representative images of thoracotomy and lung specimen harvesting from HDM-challenged mice. HDM, house dust mite–induced asthma model; HDM + Vehicle, HDM-induced asthma model treated with vehicle#; HDM + GDC-2394, HDM-induced asthma model treated with GDC-2394 dissolved in vehicle. Penh, enhanced pause. n = 10 per group. #Vehicle: DMSO diluted 1:9 (v/v) in 20% SBE-β-CD saline, combined with corn oil. Statistical significance: ****P < 0.0001 vs. Control; ns, not significant. Methacholine challenge assay to assess AHR On day 2 after the final HDM challenge, AHR was evaluated in all mice using a non-invasive pulmonary function system (Buxco Research Systems, Whole Body Plethysmography, Wilmington, NC, USA). Methacholine (Mch) challenge was performed at the end of week 4 of the experimental protocol. Pulmonary function was assessed using barometric whole-body plethysmography22, which measured changes in enhanced pause (Penh) values in response to incremental concentrations of aerosolized acetyl-β-methylcholine chloride (methacholine chloride, Mch) (CAT# S86008, Yuanye Bio, Shanghai, China). The experimental procedure was as follows: Acclimation & Baseline Measurement: Mice were placed in a chamber for a 5-min acclimation period, followed by nebulization with aerosolized PBS for 3 min to establish baseline readings. Methacholine Challenge: Mice were exposed to increasing concentrations of Mch (0, 3.125, 6.25, 12.5, 25, and 50 mg/mL in PBS). Each concentration was nebulized for 2 min to induce bronchoconstriction. Data Collection: Following each nebulization session, Penh values were recorded over a 3-min interval, and the average value was calculated. Data Presentation: Results are expressed as the percentage increase in Penh relative to baseline measurements at each dose of Mch. Post-assessment Monitoring: Body weights of all mice were recorded 24 h after the final AHR assessment. Collection and analysis of blood and bronchoalveolar lavage fluid (BALF) of mice Mice were anesthetized with isoflurane, and approximately 0.6–1.0 mL of blood was collected via the retro-orbital sinus prior to cervical dislocation. The blood samples were allowed to clot at room temperature for 2 h and then centrifuged at 3,000 × g for 20 min at 4 °C, after which the serum was carefully collected and stored at − 20 °C until further analysis. For BALF collection, the mice were positioned supine and the trachea was surgically exposed. A blunt "L"-shaped needle was inserted into the trachea through a small incision and secured with a suture to ensure stability. The lungs were lavaged five times with ice-cold sterile PBS (0.5 mL) per wash. Following a 30 s dwell time, the BALF was gently aspirated, yielding approximately 1 mL of fluid per mouse. The collected BALF was centrifuged at 3,000 × g for 10 min at 4 °C, and the resulting supernatant was stored at − 20 °C for subsequent assays. Cell pellets obtained from the BALF were resuspended in PBS, cytospun onto microscope slides, and stained using the Wright-Giemsa staining kit (CAT# G1021, Solarbio, Beijing, China). Differential cell counts were performed under a light microscope, with a minimum of 200 cells counted per slide. Eosinophil percentages were determined based on the morphological characteristics. Serum levels of IgE (CAT# MU30387) and IL-6 (CAT# MU30044), as well as levels of IL-4 (CAT# MU30385), IL-5 (CAT# MU30011), IL-13 (CAT# MU30012), IL-1β (CAT# MU30369), and IL-18 (CAT# MU30380) in the BALF, were quantified using enzyme-linked immunosorbent assay (ELISA) kits (Bioswamp® Life Science, Wuhan, China). Lung histopathology and immunohistochemistry Lung tissues were harvested by thoracic dissection (Fig. 1d, e), fixed in 4% paraformaldehyde, and embedded in paraffin. Serial 5 μm sections were stained with hematoxylin and eosin (H&E) to evaluate inflammatory cell infiltration and histopathological changes and with Alcian Blue-Periodic Acid Schiff (AB-PAS) (CAT# G1285, Solarbio) to quantify goblet cell hyperplasia and mucin secretion in bronchial epithelia. For inflammation scoring, eosinophil infiltration was graded (0–4) using a validated 5-point system23 (0: none; 1: mild; 2: moderate; 3: marked; 4: severe with structural alteration). Three random fields per section were scored. Bronchial wall thickness was measured in three regions/section using ImageJ. Mucin Area (AB-PAS⁺; % of bronchial epithelium) was quantified in ≥ 3 fields/mouse (5 mice/group). Immunohistochemistry for NLRP3 (1:300; CAT# GB114320) and IL-6 (1:300; CAT# GB11117) (Servicebio, Wuhan, China) was performed after antigen retrieval and blocking using goat anti-rabbit secondary antibody (1:200; CAT# G1213, Servicebio). Stained slides were scanned using a Pannoramic 250 FLASH scanner (3DHISTECH, Budapest, Hungary). Target⁺ area was measured in ≥ 3 fields/mouse (3 mice/group) using ImageJ. Isolation and culture of primary ASMCs The lung tissues were aseptically excised and the tracheobronchial smooth muscle layers were dissected using stereomicroscopy. Tissue fragments (~ 1 mm) were digested with 0.25% trypsin, washed with PBS (containing 1% penicillin–streptomycin), and placed in complete mouse ASMC medium (CAT# CM-M005, Pricella, Wuhan, China). Cultures were maintained in a humidified incubator at 37 °C with 5% CO2. Primary ASMCs that migrated from explants within 3–5 days exhibited spindle morphology and "hill-and-valley" patterning by day 7. Cells were passaged at 90% confluency and purified to > 99% homogeneity as confirmed by immunofluorescence. To validate the identity of primary ASMCs, double immunofluorescence staining was performed on passage-3 (P3) cells. Briefly, ASMCs grown on coverslips were fixed in 4% paraformaldehyde for 15 min, permeabilized with 0.3% Triton X-100 (CAT# 9002–93-1, Beyotime, Shanghai, China) for 10 min, and blocked with 5% BSA for 1 h at room temperature. Cells were then incubated overnight at 4 °C with a mouse monoclonal anti-α-SMA antibody (1:100, CAT# 67,735–1-Ig, Proteintech, Wuhan, China) and a rabbit polyclonal anti-calponin antibody (1:100, CAT# 13,938–1-AP, Proteintech). After washing, cells were incubated for 1 h at room temperature with FITC-conjugated goat anti-mouse IgG (1:100, CAT# SA00003-1, Proteintech) and Cy3-conjugated goat anti-rabbit IgG (1:100, CAT# SA00009-2, Proteintech). Nuclei were counterstained with DAPI (CAT# ab104139, Abcam, Cambridge, UK). Images were captured using an inverted fluorescence microscope (Leica DMi8, Germany). Co-expression of both contractile markers (α-SMA and calponin) was used to confirm the smooth muscle identity of the cultured cells and to exclude fibroblast contamination. Cell counting kit-8 (CCK-8) assay and live-cell analysis system of ASMC viability and proliferation ASMCs in logarithmic growth at passage 3 (P3) were seeded in 96-well plates at 5,000 cells per well (6 replicates per group) and cultured for 24 h. Treatments included: HDM group: 50 μg/mL HDM and HDM + GDC-2394 group: 50 μg/mL HDM combined with GDC-2394 at 5, 10, or 20 μM. Vehicle control was PBS (HDM solvent) plus 0.1% DMSO (GDC-2394 solvent). Reagent blank was medium with CCK-8 only (CAT# PF00004, Sanying). After 24, 48, or 72 h of treatment, 10 μL of CCK-8 reagent was added to each well. The optical density (OD) at 450 nm was measured 1–2 h later, when control OD values reached 1.0–1.5. Since GDC-2394 efficacy was dose-dependent, 10 μM was selected for subsequent experiments. For dynamic cell growth monitoring, ASMCs (0.1 × 106 cells per well) were cultured in 12-well plates (2 replicates per group). Cell confluence was recorded every hour for 72 h post-adhesion using live-cell imaging (Incucyte® S3, Germany), with nine fields imaged per well. EdU assay for ASMC proliferation EdU (5-Ethynyl-2′-deoxyuridine) is a thymidine analog that is incorporated into newly synthesized DNA during the S phase of replication via DNA polymerase activity. The copper-catalyzed “click” reaction with fluorescent azides enables sensitive detection of proliferating cells and provides better resolution than traditional BrdU methods. ASMCs at P3 were plated in 96-well plates (5,000 cells/well; three replicates per group) in complete medium. Following a 24-h adherence period, the following treatments were administered: HDM: 50 μg/mL HDM; HDM + GDC-2394: 50 μg/mL HDM combined with 10 μM GDC-2394; Vehicle control: PBS supplemented with 0.1% DMSO. After 48 h of treatment, cells were pulse-labeled with EdU using the BeyoClick™ EdU-555 Kit (CAT# C0075S, Beyotime) following the manufacturer’s instructions. Briefly, 50 μL of reaction mixture per well was incubated for 2 h at 37 °C. Nuclei were counterstained with Hoechst 33,342 and fluorescent images (EdU⁺ = red; nuclei = blue) were captured using an inverted fluorescence microscope (Leica DMi8, 20 × objective). Proliferation indices (% EdU⁺ cells) were calculated using ImageJ (threshold-based segmentation) from at least three random fields per well. Measurement of cytokine secretion in ASMC culture supernatants To evaluate the pro-inflammatory secretory function of ASMCs, passage-3 ASMCs were seeded in 12-well plates at a density of 1 × 105 cells per well. After 24 h of adherence, cells were treated for 48 h under the same conditions as described for the EdU assay (Control, HDM, and HDM + GDC-2394). Culture supernatants were then collected, centrifuged at 3,000 × g for 20 min at 4 °C to remove cell debris, and stored at − 20 °C until analysis. The concentrations of IL-6, IL-1β, and IL-18 were measured using the ELISA kits described above. All measurements were performed in five independent biological replicates (n = 5 per group). Quantitative real-time PCR (qRT-PCR) analysis Total RNA was isolated from ASMCs in three groups (Control, HDM, and HDM + GDC-2394) using TRIzol™ Reagent (CAT#92,008, Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA). Cells in the HDM + GDC-2394 group were harvested following a 24-h treatment with 10 μM GDC-2394. RNA purity and concentration were determined using a spectrophotometer (NanoDrop 1000; Thermo Fisher Scientific). cDNA was synthesized from 1,000 ng total RNA per sample by reverse-transcription using the EasyScript One-Step gDNA Removal and cDNA Synthesis Kit (CAT#AE311, TransGenx, Beijing, China). Reactions were performed using PerfectStart® Green qPCR SuperMix (CAT#AQ601, TransGenx) on a CFX96 Touch™ system (Bio-Rad, Hercules, CA, USA) with the following cycling conditions: initial denaturation at 94 °C for 30 s, 40 cycles of 94 °C for 5 s, 60 °C for 15 s, and 72 °C for 10 s. Validation and analysis included melt curve analysis from 55 to 95 °C with 0.5 °C increments every 5 s. Confirmation of amplification specificity was performed by single-peak dissociation curves. Gene expression was normalized to GAPDH, and relative quantification was performed using the 2−ΔΔCT method. The primers used in the experiment were synthesized by Sangon Biotech (Shanghai, China) and the details of the primer sequences are listed in Supplementary Table S1. Western blot analysis ASMCs were lysed using RIPA cell lysis buffer. Total protein was extracted from six T25 cell culture flasks for western blot analysis. Protein concentration was evaluated using the bicinchoninic acid quantification kit and 30 μg of protein from each group was subjected to electrophoretic separation on a 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis gel. Proteins were transferred to a polyvinylidene fluoride membrane with a pore size of 0.45 μm (CAT#IPVH00010, Merck Millipore, Ireland). The membrane was incubated overnight at 4 °C with the corresponding primary antibodies. The primary antibodies used were as follows: anti-NLRP3 antibody (1:1000, CAT#ab263899, Abcam), anti-IL-6 antibody (1:1000, CAT#ab259341, Abcam), anti-p-JAK2 antibody (1:1000, CAT#3771S, Cell Signaling Technology, Inc.), anti-p-STAT3 (1:1000, CAT#ab76315, Abcam), anti-JAK2 antibody (1:1000, CAT#ab108596, Abcam), anti-STAT3 antibody (1:1000, CAT#ab68153, Abcam), and anti-β-actin antibody (1:5000, CAT#66,009–1-Ig, Sanying Biotech). The next day, the membrane was washed with TBST and incubated with the following secondary antibodies: goat anti-mouse secondary antibody (CAT#RGAM001, 1:3000, Sanying Biotech) for the anti-β-actin antibody and goat anti-rabbit secondary antibody (CAT#RGAR001, 1:3000, Sanying Biotech) for all other primary antibodies. A standard ECL chemiluminescence detection kit (CAT#PK10001, Sanying Biotech) was used to detect the proteins. The western blot membranes were scanned using ChemiDoc™ XRS + (Bio-Rad) and Image Lab™ software. ImageJ software was used to analyze the grayscale values of the protein bands. Expression levels were quantified in relative units normalized to β-actin intensity. IL-6 rescue experiment To determine whether IL-6 functionally mediates the effects of NLRP3 inhibition on ASMC proliferation and JAK2/STAT3 signaling, rescue experiments were performed. Passage-3 ASMCs were divided into four groups: (1) Control (PBS + 0.1% DMSO), (2) HDM (50 μg/mL), (3) HDM + GDC-2394 (50 μg/mL HDM + 10 μM GDC-2394), and (4) HDM + GDC-2394 + recombinant mouse IL-6 (rmIL-6) (50 μg/mL HDM + 10 μM GDC-2394 + 50 ng/mL rmIL-6; CAT#ab9731, Abcam, Cambridge, UK). The working concentration of rmIL-6 was selected based on previous studies demonstrating that 25 ng/mL IL-6 is sufficient to induce STAT3 phosphorylation and DNA synthesis in smooth muscle cells via the JAK2/STAT3 pathway24. The lyophilized rmIL-6 was reconstituted in sterile deionized water to a stock concentration of 0.1 mg/mL according to the manufacturer’s instructions, aliquoted, and stored at − 20 °C; the working solution was freshly diluted in complete culture medium immediately before use. All treatments were applied simultaneously for 48 h. Cell viability was assessed by the CCK-8 assay as described above, with 6 replicates per group. For signaling analysis, total protein was extracted and subjected to western blotting for p-JAK2, JAK2, p-STAT3, STAT3, and β-actin following the same protocol as described above, with 3 biological replicates per group. Statistical analysis All statistical analyses were performed using GraphPad Prism 10 software (GraphPad Software, Inc., USA). Data are presented as mean ± standard deviation (SD). Comparisons among the four groups (Control, HDM, HDM + Vehicle, and HDM + GDC-2394) were performed using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test for multiple comparisons. All statistical tests were two-sided. A P value < 0.05 was considered statistically significant. Results Assessment of mouse body weight and AHR All mice were euthanized at 7–8 weeks of age by decapitation. The mean body weight was 20.97 ± 0.81 g in the Control group, 18.21 ± 0.47 g in the HDM group, 18.46 ± 0.32 g in the HDM + Vehicle group, and 18.80 ± 0.68 g in the HDM + GDC-2394 group. Body weights in the HDM, HDM + Vehicle, and HDM + GDC-2394 groups were all significantly lower than those in the Control group (all P < 0.0001). No significant difference was observed between the HDM and HDM + Vehicle groups (P = 0.2066) (Supplementary Table S1). AHR was evaluated by measuring Penh values in response to increasing doses of aerosolized Mch (0–50 mg/mL). The HDM group exhibited progressively elevated Penh values compared with the Control group. The HDM + Vehicle group showed a similar dose-dependent pattern, with no significant difference from the HDM group at any Mch concentration (all P > 0.05; Supplementary Table S1). GDC-2394-treated mice displayed lower Penh values than the HDM group, particularly at higher Mch concentrations (Fig. 1c). Representative images of thoracotomy and lung specimen harvesting are shown in Fig. 1d and e. Effect of GDC-2394 on inflammatory factors in serum and BALF of HDM-induced asthma mice To investigate the inflammatory status and NLRP3 activation in the HDM-induced chronic asthma model, we measured IgE and IL-6 levels in serum and BALF, assessed eosinophil proportions in BALF smears, and quantified type 2 cytokines (IL-4, IL-5, IL-13) and NLRP3-related cytokines (IL-1β, IL-18) in BALF. One-way ANOVA revealed a significant overall effect of group for all measured biomarkers (all P < 0.001; Table 1). IgE levels in serum and BALF, IL-6 levels in serum and BALF, IL-1β, IL-18, IL-4, IL-5, IL-13, and eosinophil proportions were all significantly elevated in the HDM group compared with the Control group (Tukey’s test, all P < 0.001). The HDM + Vehicle group showed no significant differences from the HDM group in any of these parameters (Tukey’s test, all P > 0.05; Table 1), confirming that the vehicle had no independent immunomodulatory effect. Table 1Quantitative levels of biomarkers in serum and bronchoalveolar lavage fluid (n = 10).GroupsSerumBALFIgE(ng/mL)IL-6(pg/mL)Eos%IgE(ng/mL)IL-4(pg/mL)IL-5(pg/mL)IL-13(pg/mL)IL-1β(pg/mL)IL-18(pg/mL)IL-6(pg/mL)Control (A)196.53 ± 34.9237.16 ± 4.916.93 ± 2.3235.58 ± 8.5145.34 ± 9.7345.42 ± 3.8124.68 ± 4.37114.53 ± 53.8460.56 ± 17.1534.62 ± 8.89HDM (B)617.39 ± 98.7380.58 ± 13.8331.28 ± 8.11143.96 ± 26.96128.66 ± 16.8564.24 ± 7.36188.06 ± 33.42790.50 ± 117.58661.29 ± 78.1695.84 ± 10.63HDM + Vehicle (C)568.34 ± 196.3974.08 ± 27.5134.22 ± 10.45132.10 ± 53.62118.84 ± 33.5259.45 ± 14.65172.76 ± 66.47728.66 ± 233.89611.74 ± 155.4888.73 ± 21.15HDM + GDC-2394 (D)461.15 ± 54.2059.57 ± 10.5830.70 ± 8.0874.07 ± 18.9199.79 ± 17.2454.72 ± 5.6073.91 ± 22.02364.51 ± 107.79341.79 ± 79.8261.39 ± 11.85F value26.9213.6626.1125.5730.768.2040.8948.7583.1040.08p value < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.00010.0003 < 0.0001 < 0.0001 < 0.0001 < 0.0001Tukey’s test(adj. p value)A-B < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.00010.0002 < 0.0001 < 0.0001 < 0.0001 < 0.0001A-C < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.00010.0060 < 0.0001 < 0.0001 < 0.0001 < 0.0001A-D < 0.00010.0216 < 0.00010.0481 < 0.00010.10640.03610.0023 < 0.00010.0007B-C0.77400.81350.83560.83720.73020.62630.81480.77290.65980.6688B-D0.02120.03440.99840.00010.02160.0955 < 0.0001 < 0.0001 < 0.0001 < 0.0001C-D0.17480.21850.74780.00130.20380.6361 < 0.0001 < 0.0001 < 0.00010.0005Data are presented as mean ± SD. Comparisons among the four groups (A–D) were performed by one-way ANOVA followed by Tukey’s multiple comparisons test. BALF, bronchoalveolar lavage fluid; IgE, immunoglobulin E; IL, interleukin; Eos%, eosinophil percentage. Group A, Control; Group B, HDM; Group C, HDM + Vehicle; Group D, HDM + GDC-2394. Quantitative levels of biomarkers in serum and bronchoalveolar lavage fluid (n = 10). Tukey’s test (adj. p value) Data are presented as mean ± SD. Comparisons among the four groups (A–D) were performed by one-way ANOVA followed by Tukey’s multiple comparisons test. BALF, bronchoalveolar lavage fluid; IgE, immunoglobulin E; IL, interleukin; Eos%, eosinophil percentage. Group A, Control; Group B, HDM; Group C, HDM + Vehicle; Group D, HDM + GDC-2394. GDC-2394 treatment significantly reduced the levels of IgE in serum (P = 0.0212 vs. HDM), IgE in BALF (P = 0.0001), IL-4 (P = 0.0216), IL-13 (P < 0.0001), IL-1β (P < 0.0001), IL-18 (P < 0.0001), and IL-6 in BALF (P < 0.0001) and serum (P = 0.0344). No significant difference in eosinophil proportions was observed among the HDM, HDM + Vehicle, and HDM + GDC-2394 groups (P = 0.9984). IL-5 showed a trend toward reduction with GDC-2394 treatment but did not reach significance (P = 0.0955). Table 1 summarizes the biomarker levels across the four groups. Supplementary Fig. S1 illustrates the trends in these results. Effect of GDC-2394 on pulmonary histopathology and Immunohistochemistry in asthmatic mice To further evaluate the effects of GDC-2394 on pulmonary histopathology, lung sections were examined 24 h after Mch stimulation. H&E staining revealed marked inflammatory cell infiltration in the peribronchiolar and perivascular regions in HDM-challenged mice, with inflammation scores significantly increased in the HDM group (3.50 ± 0.24) and HDM + Vehicle group (3.60 ± 0.35) compared with the Control group (0.97 ± 0.33; both P < 0.0001). No significant difference was observed between the HDM and HDM + Vehicle groups. GDC-2394 treatment significantly reduced the inflammation score to 1.83 ± 0.32 (P < 0.0001 vs. HDM) (Fig. 2a, c). GDC-2394 ameliorates HDM-induced pulmonary pathology: Histological and mucin analysis. (a) Representative hematoxylin and eosin (H&E)-stained lung sections showing peribronchiolar regions (upper row: 200 × ; lower row: 400 ×). (b) Representative Alcian Blue–Periodic Acid Schiff (AB-PAS)-stained sections of bronchial epithelium (upper row: 200 × ; lower row: 400 ×). (c) Inflammation scores. (d) Bronchial smooth muscle thickness.(e) Goblet cell-to-epithelial cell ratio. (f–h) Quantitative analysis of AB-positive, PAS-positive, and AB-PAS-positive epithelial cell areas. Data are presented as mean ± SD (n = 10 for c and d; n = 5 for e–h). Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant. Bronchial smooth muscle thickness was significantly increased in HDM-treated mice (11.40 ± 1.40 μm) compared with controls (6.04 ± 0.34 μm; P < 0.0001) and was reduced following GDC-2394 treatment (8.76 ± 0.89 μm; P < 0.001 vs. HDM), with no difference between the HDM and HDM + Vehicle groups (Fig. 2d). AB-PAS staining further demonstrated pronounced goblet cell hyperplasia and mucus hypersecretion in the HDM and HDM + Vehicle groups compared with controls (all P < 0.0001), whereas GDC-2394 markedly decreased goblet cell proportion and mucus production (Fig. 2b, e–h). Immunohistochemical analysis of NLRP3 and IL-6 expression in the peribronchial region showed that both NLRP3 and IL-6 levels were markedly increased in the HDM and HDM + Vehicle groups compared with the control group (all P < 0.0001), with no significant difference between the two groups. In contrast, GDC-2394 treatment significantly attenuated the HDM-induced upregulation of NLRP3 and IL-6 (all P < 0.0001, Fig. 3a–d). Of note, NLRP3 and IL-6 immunoreactivity was not restricted to the airway smooth muscle layer but was also observed in the bronchial epithelium and peribronchial inflammatory infiltrate, suggesting that the in vivo effects of GDC-2394 may involve multiple peribronchial and inflammatory cell types rather than ASMCs alone. Immunohistochemical analysis of NLRP3 and IL-6 expression in the peribronchial region. (a) Representative immunohistochemical staining of NLRP3 in peribronchial regions (upper row: 200 × ; lower row: 400 ×). (b) Representative immunohistochemical staining of IL-6 in peribronchial regions (upper row: 200 × ; lower row: 400 ×). (c) Quantification of mean optical density of NLRP3. (d) Quantification of mean optical density of IL-6. Data are presented as mean ± SD (n = 3). Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparisons test. *P < 0.05, ****P < 0.0001; ns, not significant. Characterization of ASMCs and effects of GDC-2394 on cell viability and proliferation Primary ASMCs at passage 3 displayed typical spindle-shaped morphology and “hill-and-valley” growth patterns under bright-field microscopy (Fig. 4a). To confirm the smooth muscle identity of the cultured cells and address the possibility of fibroblast contamination, we performed double immunofluorescence staining using antibodies against two independent contractile markers, α-SMA and calponin. As shown in Fig. 4b, α-SMA (green) and calponin (red) were co-expressed in the cytoplasm of virtually all cells, with DAPI-stained nuclei shown in blue. Quantification of merged images confirmed that > 95% of cells were dual-positive for both markers, thereby verifying their ASMC identity. Characterization of primary ASMCs and effects of GDC-2394 on cell viability. (a) Bright-field micrographs of passage-3 (P3) primary ASMCs at 50 × , 200 × , and 400 × magnifications, showing characteristic spindle-shaped morphology and “hill-and-valley” growth pattern. (b) Double immunofluorescence staining of P3 ASMCs for α-SMA (green) and calponin (red), with DAPI nuclear counterstain (blue). Co-expression of both smooth muscle contractile markers confirmed ASMC identity; merged images demonstrate > 95% dual-positive purity. (c–e) CCK-8 cell viability assays of ASMCs treated with HDM (50 µg/mL) and escalating concentrations of GDC-2394 (0, 5, 10, 20 µM) at 24, 48, and 72 h. (f) Summary line graph of cell viability kinetics across all time points and concentrations. Data are presented as mean ± SD (n = 6 per group). Statistical significance: **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant. To investigate the effects of GDC-2394 on ASMC viability and proliferation, ASMCs were treated with HDM (50 μg/mL) combined with GDC-2394 at 0, 5, 10, and 20 μM, and CCK-8 assays were performed at 24, 48, and 72 h. At 24 h, the control group exhibited the highest cell viability, and viability decreased with increasing GDC-2394 concentrations. At 48 h, HDM-stimulated ASMCs showed significantly higher viability than controls (all P < 0.0001), and GDC-2394 reduced this HDM-induced increase in a dose-dependent manner (Fig. 4c–f). Based on these results, 10 μM GDC-2394 was selected as the optimal concentration that suppressed abnormal proliferation without inducing cytotoxicity. Dynamic live-cell imaging confirmed significant growth differences among the three groups at 48 h (Supplementary Fig. S2). To study ASMC proliferation following HDM stimulation and GDC-2394 (10 μM) treatment, we performed EdU assay at 48 h. This timing was selected based on the CCK8 assay and live cell imaging results. The results showed that at 48 h post-intervention, the proportion of EdU-positive cells in the HDM group was significantly higher than that in the control group (P = 0.0008) , whereas the GDC-2394 group showed an intermediate proportion of EdU-positive cells (P = 0.0210, Fig. 5a, b). EdU proliferation assay and ELISA analysis of cytokine secretion by ASMCs following GDC-2394 intervention. (a) Representative fluorescence images of ASMCs from the three experimental groups stained with Hoechst (blue, nuclei) and EdU (red, DNA synthesis), along with merged channels. (b) Quantification of EdU-positive cells using ImageJ software. The HDM group exhibited a significantly higher percentage of EdU-positive cells than the control group. GDC-2394 treatment resulted in an increased percentage of EdU-positive cells relative to the control group but was significantly lower than that in the HDM group, indicating that GDC-2394 partially suppressed HDM-induced DNA synthesis in ASMCs. (c–e) Concentrations of (c) IL-6, (d) IL-1β, and (e) IL-18 in ASMC culture supernatants at 48 h, measured by ELISA. Data are presented as mean ± SD (n = 3 for EdU; n = 5 for ELISA). Statistical analysis: one-way ANOVA with Tukey’s post hoc test. *P < 0.05, ***P < 0.001, ****P < 0.0001. Effect of GDC-2394 on inflammatory cytokine secretion by ASMCs To assess the secretory function of ASMCs as effector cells in airway inflammation, we measured the concentrations of IL-6, IL-1β, and IL-18 in ASMC culture supernatants at 48 h by ELISA. HDM-stimulated ASMCs secreted significantly higher levels of IL-6 (357.79 ± 29.96 vs. 97.63 ± 8.53 pg/mL, P < 0.0001), IL-1β (906.78 ± 16.70 vs. 93.39 ± 10.62 pg/mL, P < 0.0001), and IL-18 (620.02 ± 83.74 vs. 79.46 ± 9.35 pg/mL, P < 0.0001) compared with Control ASMCs. GDC-2394 (10 μM) treatment significantly reduced the secretion of all three cytokines compared with the HDM group (IL-6: 273.31 ± 9.82 pg/mL, P < 0.0001; IL-1β: 373.73 ± 25.83 pg/mL, P < 0.0001; IL-18: 322.60 ± 59.14 pg/mL, P < 0.0001), although the levels remained elevated relative to controls (all P < 0.0001). These results indicate that NLRP3 inhibition by GDC-2394 attenuates the pro-inflammatory secretory activity of ASMCs in addition to suppressing their proliferation (Fig. 5c–e). Effect of GDC-2394 on the NLRP3–IL-6/JAK2/STAT3 signaling axis in ASMCs of asthmatic mice qRT-PCR was used to examine the NLRP3-IL-6/JAK2/STAT3 signaling axis in ASMCs. The results showed that the relative mRNA levels of NLRP3(P = 0.0015) and IL-6 (P = 0.0058) were significantly higher in the HDM group than those in the control group , while the levels in the HDM + GDC-2394 group were significantly reduced compared to those in the HDM group(P = 0.0160, P = 0.0137). However, no significant difference was observed in the mRNA expression of JAK2 and STAT3 (Fig. 6a–d). Therefore, further investigation of protein expression is necessary to confirm these findings. GDC-2394 modulates NLRP3–IL-6/JAK2/STAT3 signaling in HDM-stimulated ASMCs at both transcriptional and translational levels. Total RNA was extracted from the ASMCs in the three groups (Control, HDM, and GDC-2394) and analyzed by qRT-PCR. Compared with the control group, HDM exposure significantly up-regulated (a) NLRP3 and (b) IL-6 mRNA levels (**P < 0.01), whereas GDC-2394 treatment reversed these increases (*P < 0.05). No significant differences were observed between the GDC-2394 and control groups (ns). Transcript levels of (c) JAK2 and (d) STAT3 did not differ among the groups (ns). (e–j) Protein levels of NLRP3, IL-6, total JAK2, total STAT3, pJAK2, and pSTAT3. Total JAK2 and STAT3 protein levels did not differ among the groups. HDM markedly elevated phosphorylated JAK2 (p-JAK2) and phosphorylated STAT3 (p-STAT3) relative to both the control (*P < 0.05) and GDC-2394 (*P < 0.05) groups, whereas the phosphorylation levels in the GDC-2394 and control groups were comparable (ns). *P < 0.05,**P < 0.01. ns, not significant. To further validate the protein expression of the NLRP3-IL-6-JAK2/STAT3 axis in ASMCs and investigate the lack of differences in JAK2 and STAT3 mRNA expression, we extracted proteins from the three groups of ASMCs. Western blotting showed that the relative protein expression levels of NLRP3 and IL-6 in the HDM group were significantly higher than those in the control (P = 0.0033, P = 0.0074) and HDM + GDC-2394 groups (P = 0.0356, P = 0.0014). There were differences in protein expression between the latter two groups; however, these differences were not statistically significant. Phosphorylation markers were used to assess the JAK2/STAT3 pathway status. The results indicated no significant differences in total JAK2/STAT3 protein levels among the three groups; however, significant differences were observed in p-JAK2/p-STAT3 expression. p-JAK2/p-STAT3 expression was highest in the HDM group, and there was no statistically significant difference in expression between the control and HDM + GDC-2394 groups (Fig. 6e–j). These findings suggest that GDC-2394 reduces IL-6 expression and is associated with decreased JAK2/STAT3 phosphorylation in ASMCs. Exogenous IL-6 partially reverses the inhibitory effects of GDC-2394 on ASMC proliferation and JAK2/STAT3 signaling The above results demonstrated a strong correlation between NLRP3 inhibition, reduced IL-6 secretion, and suppressed JAK2/STAT3 signaling. To test whether IL-6 functionally mediates this relationship, we performed rescue experiments by supplementing exogenous rmIL-6 (50 ng/mL) to GDC-2394-treated ASMCs. The CCK-8 assay showed that HDM stimulation increased cell viability compared with the Control group (134.01 ± 5.21% vs. 99.56 ± 5.90%, P < 0.0001), and GDC-2394 treatment reduced this HDM-induced increase (111.35 ± 3.13% vs. 134.01 ± 5.21%, P < 0.0001; Fig. 7a). Supplementation with rmIL-6 restored cell viability in the HDM + GDC-2394 + rmIL-6 group compared with the HDM + GDC-2394 group (125.08 ± 4.46% vs. 111.35 ± 3.13%, P < 0.001; Fig. 7a). However, the rescued viability remained lower than that of the HDM group (125.08 ± 4.46% vs. 134.01 ± 5.21%, P = 0.020), indicating a partial rather than complete reversal of the antiproliferative effect of GDC-2394. Exogenous IL-6 partially reverses the inhibitory effects of GDC-2394 on ASMC proliferation and restores JAK2/STAT3 phosphorylation. (a) CCK-8 cell viability assay at 48 h. HDM stimulation significantly increased cell viability compared with the Control group, and GDC-2394 treatment attenuated this increase. Supplementation with recombinant mouse IL-6 (rmIL-6; 50 ng/mL) partially restored cell viability in the HDM + GDC-2394 + rmIL-6 group relative to the HDM + GDC-2394 group, although the rescued viability remained lower than that of the HDM group. (b) Representative western blot images of p-JAK2, JAK2, p-STAT3, STAT3, and β-actin in the four experimental groups. (c) Densitometric quantification of the p-JAK2/JAK2 ratio normalized to β-actin. GDC-2394 significantly reduced JAK2 phosphorylation, and rmIL-6 supplementation restored the p-JAK2/JAK2 ratio to a level comparable to that of the HDM group. (d) Densitometric quantification of the p-STAT3/STAT3 ratio normalized to β-actin. GDC-2394 markedly suppressed STAT3 phosphorylation, and rmIL-6 supplementation significantly restored the p-STAT3/STAT3 ratio. Data are presented as mean ± SD (n = 6 for CCK-8; n = 3 for western blot). Statistical comparisons were performed using one-way ANOVA followed by Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant. Western blot analysis further confirmed that rmIL-6 supplementation restored JAK2/STAT3 signaling in GDC-2394-treated ASMCs (Fig. 7b). Densitometric quantification revealed that the normalized p-JAK2/JAK2 ratio was significantly elevated in the HDM group compared with the Control group (2.27 ± 0.26 vs. 1.01 ± 0.21, P = 0.0021) and was markedly reduced by GDC-2394 treatment to a level comparable to that of controls (1.11 ± 0.27 vs. 2.27 ± 0.26, P = 0.0035; Fig. 7c). Supplementation with rmIL-6 significantly increased the p-JAK2/JAK2 ratio compared with the HDM + GDC-2394 group (2.09 ± 0.33 vs. 1.11 ± 0.27, P = 0.0094), restoring it to a level that was not significantly different from that of the HDM group (P = 0.8548; Fig. 7c). Similarly, the normalized p-STAT3/STAT3 ratio was significantly higher in the HDM group than in the Control group (2.85 ± 0.46 vs. 1.00 ± 0.26, P = 0.0015) and was suppressed by GDC-2394 treatment (1.30 ± 0.36 vs. 2.85 ± 0.46, P = 0.0047; Fig. 7d). rmIL-6 supplementation significantly increased the p-STAT3/STAT3 ratio relative to the HDM + GDC-2394 group (2.37 ± 0.40 vs. 1.30 ± 0.36, P = 0.0349), and the restored level did not differ significantly from that of the HDM group (P = 0.4653; Fig. 7d). The full-length, uncropped gel/membrane images corresponding to the western blot data are shown in Supplementary Fig. S3–S7. Total JAK2 and STAT3 protein levels remained unchanged across all four groups. These results indicate that exogenous IL-6 can restore JAK2/STAT3 phosphorylation in the context of NLRP3 inhibition, supporting the involvement of IL-6 as a functional mediator linking NLRP3 activation to JAK2/STAT3 signaling in ASMCs. Discussion Asthma is a common chronic respiratory disease in children characterized by persistent airway inflammation, potentially leading to irreversible airway remodeling, lung function decline, and impaired quality of life25. Airway smooth muscle hypertrophy, a key pathological feature linked to hyperresponsiveness and airflow limitation, underscores current treatment limitations, which focus on symptom suppression rather than addressing underlying mechanisms, such as NLRP3 inflammasome-driven inflammation across asthma phenotypes26,27. Our study provides evidence that the NLRP3–IL-6/JAK2/STAT3 pathway is involved in the regulation of airway smooth muscle cell proliferation and type 2 inflammation in a chronic HDM-induced asthma model. Intervention with the NLRP3 inhibitor GDC-2394 attenuated bronchial smooth muscle hyperplasia and inflammatory responses in this experimental setting, suggesting that targeting NLRP3 warrants further investigation as a potential therapeutic strategy for airway remodeling in asthma. Improvements in inflammatory cell infiltration and cytokine levels further supported the importance of NLRP3 as a potential therapeutic target, although the translational relevance of these findings to pediatric asthma remains to be determined. Allergic airway inflammation models are vital for studying asthma pathogenesis, with variations in allergen use yielding diverse characteristics such as inflammation and remodeling. HDM induction over four weeks establishes chronic models with remodeling phenotypes21. C57BL/6 mice, widely used for their defined genetic background28, exhibit type 2 responses, including eosinophilia and elevated IL-4, IL-5, and IL-1329 and female mice show enhanced responses with higher IgE and AHR in some models30. Selecting three-week-old juvenile mice accurately models the effects of early allergen exposure, mirroring childhood asthma onset due to immature immune and airway systems. To confirm the specificity of GDC-2394, we included a vehicle control group in the revised experimental design. Vehicle treatment alone did not significantly affect the asthma phenotype, indicating that the therapeutic effects observed were attributable to GDC-2394 rather than to the vehicle components. Th2 cells and ILC2s are central to type 2 inflammatory asthma, driving eosinophilia and AHR through IL-4, IL-5, and IL-13 production31–36. The asthma model groups (HDM and HDM + Vehicle) exhibited significantly lower body weights, more severe AHR, and elevated type 2 cytokines, eosinophil proportions, and IgE levels compared with controls, consistent with a type 2-high inflammatory phenotype37. The comparable responses between HDM and HDM + Vehicle groups confirmed the specificity of GDC-2394. NLRP3 inhibition reduced type 2 inflammatory markers, suggesting that NLRP3 may participate in type 2 inflammatory asthma through multiple pathological mechanisms. Histological analysis of lung tissues revealed that HDM induced significant eosinophil infiltration into the peribronchial regions, with bronchial luminal narrowing and increased smooth muscle thickness. The HDM + Vehicle group exhibited comparable histopathological changes, confirming that the vehicle did not influence airway remodeling. These observations were quantitatively confirmed by inflammation scoring and measurement of smooth muscle layer thickness. AB-PAS staining is a histochemical technique used to differentiate between acidic and neutral mucopolysaccharides in tissue sections. In AB-PAS double staining, acidic mucopolysaccharides appeared blue, neutral mucopolysaccharides appeared red, and mixed types were visualized as blue or purple-blue. AB-PAS staining revealed an increase in bronchial epithelial goblet cell numbers and excessive production of both acidic and mixed mucus in the HDM group. These results are consistent with those reported by Wu Y38. Moreover, these pathological alterations were attenuated in mice treated with GDC-2394. The NLRP3 inflammasome is an intracellular sensor that detects microbial and endogenous danger signals, leading to caspase-1-dependent release of IL-1β and IL-18 and pyroptotic cell death39. Aberrant NLRP3 activation has been implicated in asthma pathogenesis, and pharmacological NLRP3 inhibition attenuates AHR and inflammatory responses in preclinical models27,40. To investigate the role of NLRP3 in airway remodeling, we developed a chronic HDM-induced asthma model that mimics severe asthma phenotypes. IL-6 is primarily produced by inflammatory and airway epithelial cells and its levels in the airways are closely associated with asthma severity. IL-6 is a multifunctional cytokine with dual pro- and anti-inflammatory functions. It plays a significant role in the pathogenesis of asthma, particularly in refractory asthma41. Whether IL-6 can serve as a key biomarker for asthma remains controversial42; however, multiple studies have shown that IL-6 levels are significantly elevated in the blood and BLAF of patients with asthma, particularly in those with refractory asthma and during active asthma episodes. IL-6 levels are associated with the severity of airway inflammation and lung function, including Forced Expiratory Volume in 1 s (FEV1) 43,44. IL-6 levels are influenced by viral infections and obesity, both of which are risk factors for asthma exacerbation45,46. Inhibition of the STAT3 signaling pathway activation can attenuate airway inflammation and remodeling in asthma47,48. Multiple studies have confirmed that inhibiting JAK2 activity effectively suppresses eosinophil infiltration and airway inflammation in allergic asthmatic mice, thereby improving asthma symptoms49,50. IL-6 binds to soluble IL-6 receptors, which then activate glycoprotein 130 on the cell surface, leading to activation of the JAK2/STAT3 signaling pathway50. We measured IL-6 levels in the serum and BALF supernatants via ELISA and found that the levels in the HDM group were significantly higher than those in the control group; however, treatment with GDC-2394 reduced IL-6 levels compared to the HDM group. Our findings demonstrate that NLRP3 promotes IL-6 expression in the serum and BALF of asthmatic mice. Based on previous studies, we explored the relationship between NLRP3 and the IL-6/JAK2/STAT3 pathway to clarify their roles in the mechanisms underlying bronchial asthma. Therefore, we performed immunohistochemical validation of key upstream targets in lung tissue pathology sections. We conducted separate immunohistochemical staining for NLRP3 and IL-6, and found that both were highly expressed around the bronchi in the asthma model group, whereas their expression levels were significantly reduced in the GDC-2394 group. The expression levels in both the asthma model and GDC-2394 groups were higher than those in the control group. HDM inhalation activates the NLRP3 inflammasome in alveolar macrophages, promoting caspase-1 maturation and IL-1β secretion17. Previous studies have reported improved airway smooth muscle thickening in NLRP3-KO asthmatic mice, although these observations were limited to histological analyses51. In vascular smooth muscle cells, NLRP3 activation promotes phenotypic conversion and proliferation, and MCC950 treatment alleviates vascular inflammation52. Extending these findings to the airway, our study showed that 10 µM GDC-2394 suppressed HDM-induced ASMC proliferation at 48 h, as confirmed by CCK-8, live-cell imaging, and EdU assays, without inducing cytotoxicity. This concentration is consistent with the effective range reported for GDC-2394 in other cellular models53. These data suggest that NLRP3 inhibition attenuates the abnormal proliferative phenotype of ASMCs, although indirect effects through reduced inflammatory signaling cannot be excluded. Furthermore, ASMCs are increasingly recognized as immunomodulatory effector cells54. Our ELISA analysis showed that HDM stimulation enhanced IL-6, IL-1β, and IL-18 secretion by primary ASMCs, and GDC-2394 treatment significantly attenuated the secretion of all three cytokines, suggesting that NLRP3 inhibition not only suppresses ASMC proliferation but also partially reverses their pro-inflammatory secretory phenotype. Our functional assessment focused on the proliferative dimension of airway remodeling, which contributes to the increase in airway smooth muscle mass in chronic asthma. Other ASMC functions relevant to remodeling, in particular contractility and migration, were not directly assessed in the present study. Although our proliferation, cytokine-secretion, signaling, and IL-6 rescue data are collectively consistent with a role for NLRP3 in restraining the abnormal ASMC phenotype, dedicated functional assays such as collagen gel contraction and Transwell migration would be valuable in future work to further connect these molecular findings to airway remodeling function. Because GDC-2394 was administered systemically and NLRP3 is broadly expressed across peribronchial compartments, including the bronchial epithelium and infiltrating immune cells, the in vivo reduction in airway smooth muscle hyperplasia should be interpreted as the integrated outcome of NLRP3 inhibition across multiple cell types rather than a direct effect on ASMCs alone. Indeed, the beneficial effects of GDC-2394 observed in this study are unlikely to be mediated exclusively through ASMCs. Asthma is a complex, multicellular disease involving coordinated interactions among eosinophils, mast cells, macrophages, dendritic cells, Th2 cells, and group 2 innate lymphoid cells (ILC2s)2. NLRP3 is expressed in multiple immune cell types, including macrophages, neutrophils, and dendritic cells55, and can also function as a transcription factor promoting Th2 differentiation independently of the inflammasome56. Its pharmacological inhibition by a systemically administered agent such as GDC-2394 would be expected to modulate inflammatory responses in multiple cellular compartments simultaneously. Indeed, Ma et al. demonstrated that in HDM-induced asthma, NLRP3 promoted caspase-1 activation and IL-1β maturation specifically in alveolar macrophages, and that NLRP3 deficiency attenuated Th2 cytokine production and eosinophilic inflammation17. Similarly, our in vivo data showed that GDC-2394 reduced eosinophilic infiltration, suppressed type 2 cytokines (IL-4, IL-5, IL-13), and attenuated IgE and IL-1β/IL-18 levels in BALF, effects that likely reflect the modulation of both immune and structural cell populations. Therefore, the reduction in airway smooth muscle hyperplasia following GDC-2394 treatment may represent the net outcome of direct effects on ASMCs combined with indirect effects mediated by the attenuation of the inflammatory milieu27. Future studies employing cell-type-specific conditional knockout models, co-culture systems, and comprehensive immune cell profiling will be essential to delineate the relative contributions of immune and stromal compartments to the therapeutic effects of NLRP3 inhibition in asthma57. Finally, we investigated the inflammatory signaling pathways through which NLRP3 mediates the abnormal activation and proliferation of ASMCs. Previous studies have identified the IL-6/JAK2/STAT3 pathway as a key intracellular signaling pathway, which is widely involved in physiological and pathological processes including cell proliferation, differentiation, immune regulation, inflammatory responses, and tumorigenesis58. IL-6 binding to its membrane receptor activates the non-receptor tyrosine kinase JAK2, which in turn phosphorylates and activates STAT3. Activated STAT3 forms dimers, translocates into the nucleus, binds to target gene promoters, and regulates transcription. Ren et al.18 found that inhibition of the IL-6/JAK2/STAT3 pathway can improve the pathological manifestations of asthma. Therefore, to confirm whether NLRP3 also influences ASMCs through this pathway, we examined the expression levels of NLRP3, IL-6, JAK2, and STAT3 in the three groups of ASMCs. We found that the model group showed high mRNA expression levels of NLRP3 and IL-6, whereas the GDC-2394 group showed decreased expression. Notably, there were no significant differences in the mRNA levels of JAK2 and STAT3 among the three groups. Further validation of their protein expression levels revealed that while the total protein levels of NLRP3, IL-6, JAK2, and STAT3 matched the qRT-PCR results, the phosphorylated forms of JAK2 and STAT3 showed significant differences among the groups. In the HMD group, the expression levels of NLRP3, IL-6, p-JAK2, and p-STAT3 were significantly higher than that in the control group, whereas their expression levels in cells treated with GDC-2394 were not significantly different from those in the control group. These data suggest that NLRP3 inhibition is associated with reduced IL-6-dependent JAK2/STAT3 phosphorylation, which may contribute to the suppression of the proliferative phenotype of ASMCs. Fig.S9 demonstrates the corresponding cellular signaling pathway for visual representation. These findings are consistent with those of Wang et al. that showed that Abi1 (Abelson interactor 1) mediates airway smooth muscle cell proliferation and airway remodeling through the JAK2/STAT3 signaling pathway19. To further explore the functional role of IL-6 in this signaling axis, we performed rescue experiments by supplementing exogenous rmIL-6 to GDC-2394-treated ASMCs. The addition of rmIL-6 partially reversed both the reduction in cell viability and the suppression of JAK2/STAT3 phosphorylation caused by GDC-2394, suggesting that IL-6 acts as a downstream mediator linking NLRP3 activation to JAK2/STAT3-driven ASMC proliferation. The observation that the rescue was partial rather than complete may reflect the involvement of additional NLRP3-dependent effectors, such as IL-1β and IL-18, both of which were also reduced by GDC-2394 in our ELISA analysis. Further studies using combinatorial cytokine rescue or individual neutralization approaches would help clarify the relative contributions of each effector to the proliferative phenotype. This study has several limitations. First, it focused exclusively on a high type 2 inflammation asthma model, without investigating other asthma phenotypes. Second, due to funding constraints, NLRP3 and IL-6 knockout mice were not utilized, limiting the ability to evaluate their specific roles in the pathway. Third, although the NLRP3 mechanism is complex and involves multiple downstream pathways, only one pathway was examined, necessitating further validation. Fourth, although we included an HDM + Vehicle control group to confirm the specificity of GDC-2394, additional control groups such as PBS + Vehicle and PBS + GDC-2394 were not included; however, given that the vehicle alone showed no significant effect on the asthma phenotype, these additional groups are unlikely to alter the main conclusions. Additionally, only the oral NLRP3-specific inhibitor GDC-2394 was tested, without assessing its potential toxicity or long-term risks. Fifth, our in vitro assessment of ASMC function was limited to proliferation and cytokine secretion and did not include direct functional assays of contractility (e.g., collagen gel contraction) or migration (e.g., Transwell assays). Therefore, whether NLRP3 inhibition also affects the contractile and migratory behavior of ASMCs—additional functional contributors to airway remodeling—remains to be determined in future studies. Sixth, because GDC-2394 was administered systemically and NLRP3 is broadly expressed in airway epithelial, structural, and inflammatory cells, our in vivo design does not allow the anti-remodeling effects to be attributed specifically to ASMCs, and the relative contributions of direct effects on ASMCs versus indirect effects secondary to a dampened inflammatory milieu cannot be distinguished. Cell-type-specific conditional knockout models, locally restricted drug delivery, and comprehensive immune-cell profiling will be needed to clarify these compartment-specific contributions. Therefore, future studies are warranted to confirm and expand upon these findings. Conclusions In this study, we developed a chronic HDM-induced asthma model in juvenile mice and demonstrated that the oral NLRP3 inhibitor GDC-2394 attenuated type 2 airway inflammation, reduced bronchial smooth muscle hyperplasia, and suppressed the IL-6/JAK2/STAT3 signaling axis in primary ASMCs. IL-6 rescue experiments further suggested that IL-6 may act as a functional mediator linking NLRP3 inhibition to JAK2/STAT3-associated ASMC proliferation. These findings provide experimental evidence that pharmacological inhibition of NLRP3 may represent a potential therapeutic approach for airway remodeling in asthma, although further validation in other asthma phenotypes and clinical settings is needed. Supplementary Information Supplementary Information.